Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

ELI LILLY & Co Director's Dealing 2022

Feb 12, 2022

29745_dirs_2022-02-11_c7eafcbc-d6f6-4663-b927-d3bc3e67181d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2022-02-09

Reporting Person: White Anne E. (SVP & Pres-Lilly Neuroscience)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2022-02-09 Common Stock A 11348 $243.27 Acquired 50352 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2022-02-09 Restricted Stock Unit $ A 7264 Acquired 2023-02-01 Common Stock (7264.0) Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.